Prostate-specific membrane antigen (PSMA): Current benefits and future value

Seminars in Surgical Oncology

Volumn 18, Issue 1, 2000, Pages 10-16

  Elgamal, Abdel Aziz A ^a   Holmes, Eric H ^a   Su, Sai L ^a   Tino, William T ^a   Simmons, Sheila J ^a   Peterson, Mary ^a   Greene, Thomas G ^a   Boynton, Alton L ^a   Murphy, Gerald P ^b  

^a Northwest Biotherapeutics Inc   (United States)

^b PACIFIC NORTHWEST RESEARCH INSTITUTE   (United States)

Author keywords

Adenocarcinoma; Biological tumor markers; Enzyme linked immunosorbent assay; Epitopes; Human chromosomes pair 11; Immunohistochemistry; Incidence; Indium radioisotopes; Lymphatic metastasis; Monoclonal antibodies; Neoplasm circulating cells; Neoplasm invasiveness; Neoplasm metastasis; Predictive value of tests; Prostate specific antigen; Prostatic hyperplasia; Prostatic neoplasms; Radioimmunodetection; Reverse transcriptase polymerase chain reaction; Semen; Sensitivity and specificity; Staining; messenger RNA; Survival rate; Western blotting

Indexed keywords

CAPROMAB PENDETIDE IN 111; MESSENGER RNA; MONOCLONAL ANTIBODY; PROSTATE SPECIFIC MEMBRANE ANTIGEN; TUMOR MARKER;

CANCER CLASSIFICATION; CANCER INVASION; CANCER STAGING; CHROMOSOME 11; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOSCINTIGRAPHY; MALE; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE DISEASE; PROSTATE HYPERTROPHY; PROSTATE TUMOR; RADIOIMMUNOASSAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SEMINAL PLASMA; SERUM;

ANTIGENS, SURFACE; BLOTTING, WESTERN; CARBOXYPEPTIDASES; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; NEOPLASM METASTASIS; NEOPLASM STAGING; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

EID: 0033986204     PISSN: 87560437     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2388(200001/02)18:1<10::AID-SSU3>3.0.CO;2-V     Document Type: Review

References (55)

1. Landis SH, Murray T, Bolden S, Wingo PA: Cancer statistics, 1999. CA Cancer Clin 1999;49:8-31.
2. Smart CR: The results of prostate carcinoma screening in the U.S. as reflected in the Surveillance, Epidemiology, and End Results Program. Cancer 1997;80:1835-1844.
3. Brawley OW: Prostate carcinoma incidence and patient mortality: the effects of screening and early detection. Cancer 1997;80:1857-1863.
4. Aus G, Hugosson J, Norlén L: Need for hospital care and palliative treatment for prostate cancer treated with noncurative intent. J Urol 1995;154(2 Pt 1):466-469.
5. Douglas TH, Morgan TO, McLeod DG, et al: Comparison of serum prostate specific membrane antigen, prostate specific antigen, and free prostate specific antigen levels in radical prostatectomy patients. Cancer 1997;80:107-114.
6. Elgamal AA, Petrovich Z, Van Poppel H, Baert L: The role of prostate specific antigen in the management of prostate cancer. In: Petrovich Z, Baert L, Brady LW (eds): "Carcinoma of the prostate: innovations in management." New York: Springer; 1996. p. 179-196.
7. Maraj BH, Whelan P, Markham AF: Prostate-specific membrane antigen [Review]. Br J Urol 1998;81:523-528.
8. Murphy GP, Elgamal AA, Su SL, et al: Current evaluation of the tissue localization and diagnostic utility of prostate-specific membrane antigen [Review]. Cancer 1998;83:2259-2269.
9. Tjoa BA, Elgamal AA, Murphy GP: Vaccine therapy for prostate cancer. Urol Clin North Am 1999;26:365-374.
10. Abdel-Nabi H, Wright GL, Gulfo JV: Monoclonal antibodies and radioimmunoconjugates in the diagnosis and treatment of prostate cancer [published erratum appears in Semin Surg Urol 1992;10:138]. Semin Surg Urol 1992;10:45-54.
11. 111in-labeled monocolonal antibody 7E11-C5.3 (CYT-356). Prostate 1991;18: 229-241.
12. Israeli RS, Miller WH Jr, Su SL, et al: Sensitive nested reverse transcription polymerase chain reaction detection of circulating prostatic tumor cells: comparison of prostate-specific membrane antigen and prostate-specific antigen-based assays. Cancer Res 1994;54: 6306-6310.
13. Bostwick DG, Pacelli A, Blute M, et al: Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer 1998;82:2256-2261.
14. Horoszewicz JS, Kawinski E, Murphy GP: Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res 1987;7:927-936.
15. Silver DA, Pellicer I, Fair WR, et al: Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997;3:81-85.
16. Troyer JK, Becket ML, Wright GL Jr: Detection and characterization of prostate-specific membrane antigen (PSMA) in tissue extract and body fluids. Int J Cancer 1995;62:552-528.
17. Fair WR, Israeli RS, Heston WD: Prostate-specific membrane antigen [Review]. Prostate 1997;32:140-148.
18. Gregorakis AK, Holmes EH, Murphy GP: Prostate-specific membrane antigen: current and future utility [Review]. Semin Urol Oncol 1998;16:2-12.
19. Liu H, Moy P, Kim S, et al: Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res 1997;57:3629-3634.
20. O'Keefe DS, Su SL, Bacich DJ, et al: Mapping, genomic organization and promoter analysis of the human prostate-specific membrane antigen gene. Biochim Biophys Acta 1998;1443:113-127.
21. Parks GD, Lamb RA: Topology of eukaryotic type II membrane proteins: importance of N-terminal positively charged residues flanking the hydrophobic domain. Cell 1991;64:777-787.
22. Wright GL Jr, Grob BM, Haley C, et al: Upregulation of prostate-specific membrane antigen after androgen deprivation therapy. Urology 1996;48:326-334.
23. Kawakami M, Nakayama J: Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situ hybridization. Cancer Res 1997;57:2321-2324.
24. Su SL, Huang I, Fair WR, et al: Alternatively spliced variants of prostate-specific membrane antigen RNA: ratio of expression as a potential measurement of progression. Cancer Res 1995;55:1441-1443.
25. Grauer LS, Lawler KD, Marignac JL, et al: Identification, purification, and subcellular localization of prostate-specific membrane antigen PSM' protein in the LNCaP prostatic carcinoma cell line. Cancer Res 1998;58:4787-4789.
26. Murphy GP, Greene TG, Tino WT, et al: Isolation and characterization of monoclonal antibodies specific for the extracellular domain of prostate specific membrane antigen. J Urol 1998;160(6 Pt 2):2396-2401.
27. Holmes EH, Tino WT, Green TG, et al. Development and characterization of monoclonal antibodies specific for extracellular domain of prostate-specific membrane antigen [Abstract]. Cancer Biother Radiopharm 1998;13:55A.
28. Figg WD, Ammerman K, Patronas N, et al: Lack of correlation between prostate-specific antigen and the presence of measurable soft tissue metastases in hormone-refractory prostate cancer. Cancer Invest 1996;14:513-517.
29. Kramer S, Gorich J, Gottfried HW, et al: Sensitivity of computed tomography in detecting local recurrence of prostatic carcinoma following radical prostatectomy. Br J Radiology 1997;70:995-999.
30. Fowler JE Jr, Brooks J, Pandey P, Seaver LE: Variable histology of anastomotic biopsies with detectable prostate specific antigen after radical prostatectomy. J Urol 1995;153(3 Pt 2):1011-1014.
31. Elgamal AA, Troychak MJ, Murphy GP: ProstaScint® may enhance identification of prostate cancer recurrence after prostatectomy, radiation, or hormone therapy: analysis of 136 scans of 100 patients [Review]. Prostate 1998;37:261-269.
32. Maguire RT, Pascucci VL, Maroli AN, Gulfo JV: Immunoscintigraphy in patients with colorectal, overian and prostate cancer. Results with site-specific immunoconjugates [Review]. Cancer 1993;72(11 Suppl):3453-3462.
33. 111indium-labeled monoclonal antibody CYT-356. J Urol 1994;152(6 Pt 1):1952-1955.
34. Kahn D, Williams RD, Haseman MK, et al: Radioimmunoscintigraphy with In-111-labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy. J Clin Oncol 1998;16:284-289.
35. Hinkle GH, Burgers JK, Neal CE, et al: Multicenter radioimmunoscintigraphic evaluation of patients with prostate carcinoma using Indium-111 capromab pendetide. Cancer 1998;83:739-747.
36. Hinkle GH, Burgers JK, Olsen JO, et al: Prostate cancer abdominal metastases detected with Indium-111 capromab pendetide. J Nucl Med 1998;39:650-652.
37. Chengazi VU, Feneley MR, Ellison D, et al: Imaging prostate cancer with Technetium-99m-7E11-C5.3 (CYT-351). J Nucl Med 1997;38:675-682.
38. Haseman MK, Reed NL, Rosenthal SA. Monoclonal antibody imaging of occult prostate cancer in patients with elevated prostate-specific antigen. Positron emission tomography and biopsy correlation. Clin Nucl Med 1996;21:704-713.
39. 111indium labeled CYT-356 for the detection of occult prostate cancer recurrence. J Urol 1994;152(5 Pt 2):1490-1495.
40. 111inium-capromab pendetide immunoscintigraphy in the prediction of lymph node involvement in high-risk prostate carcinoma patients. Cancer 1999;85:1586-1592.
41. 111 capromab monoclonal antibody: utility in differentiating local versus distant relapse after radical prostatectomy [Abstract]. J Urol 1997;157:205.
42. Murphy GP, Maguire RT, Rogers B, et al: Comparison of serum PSMA, PSA levels with results of Cytogen-356 ProstaScint scanning in prostatic cancer patients. Prostate 1997;33:281-285.
43. Tremblay J, Frenette G, Tremblay RR, et al: Excretion of three major prostatic secretory proteins in urine of normal men and patients with benign prostatic hypertrophy or prostate cancer. Prostate 1987;10:235-243.
44. Murphy GP, Holmes EH, Boynton AL, et al: Comparison of prostate specific antigen, prostate specific membrane antigen, and LNCaP-based enzyme-linked immunosorbent assay in prostatic cancer patients and patients with benign prostatic enlargement. Prostate 1995;26:164-168.
45. Murphy G, Ragde H, Kenny G, et al: Comparison of prostate specific membrane antigen, and prostate specific antigen levels in prostatic cancer patients. Anticancer Res 1995;15:1473-1479.
46. Rochon YP, Horoszewicz JS, Boynton AL, et al: Western blot assay for prostate-specific membrane antigen in serum of prostate cancer patients. Prostate 1994;25:219-223.
47. rd, Holmes EH, Boynton AL, et al: Method for identifying prostate cells in semen using flow cytometry. Prostate 1998;36:181-188.
48. Gomella LG, Raj GV, Moreno JG. Reverse transcriptase polymerase chain reaction for prostate specific antigen in the management of prostate cancer [Review]. J Urol 1997;158:326-337.
49. Elgamal AA, Ectors NL, Widyaputra SS, et al: [Reply by authors to letters] Re: Detection of prostate specific antigen in pancreas and salivary glands: a potential impact on prostate cancer overestimation. J Urol 1997;157:1373-1377.
50. Ellis WJ, Vessella RL, Corey E, et al: Value of reverse transcriptase polymerase chain reaction assay in preoperative staging and followup of patients with prostate cancer. J Urol 1998;159:1134-1138.
51. Cama C, Olsson CA, Raffo AJ, et al: Molecular staging of prostate cancer. II. A comparison of the application of an enhanced reverse transcriptase polymerase chain reaction assay for prostate specific antigen versus prostate specific membrane antigen. J Urol 1995;153:1373-1378.
52. Grasso YZ, Gupta MK, Levin HS, et al: Combined nested RT-PCR assay for prostate-specific antigen and prostate-specific membrane antigen in prostate cancer patients: correlation with pathological stage. Cancer Res 1998;58:1456-1459.
53. Loric S, Dumas F, Eschwege P, et al: Enhanced detection of hematogenous circulating prostatic cells in patients with prostate adenocarcinoma by using nested reverse transcription polymerase chain reaction assay based on prostate-specific membrane antigen. Clin Chem 1995;41(12 Pt 1):1698-1704.
54. Sokoloff MH, Tso CL, Kaboo R, et al: Quantitative polymerase chain reaction does not improve preoperative prostate cancer staging: a clinicopathological molecular analysis of 121 patients. J Urol 1996;156:1560-1566.
55. Zhang Y, Zippe CD, Van Lente F, et al: Combined nested reverse transcription-PCR assay for prostate-specific antigen and prostate-specific membrane antigen in detecting circulating prostatic cells. Clin Cancer Res 1997;3:1215-1220.